Presynaptic monoaminergic terminal

Presynaptic monoaminergic terminals are specialized axonal endings responsible for the synthesis, storage, and release of monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine (StatPearls, 2023). These structures contain essential proteins including the vesicular monoamine transporter 2 (VMAT2), which packages neurotransmitters into vesicles, and plasma membrane transporters (DAT, SERT, NET) that terminate signaling through reuptake (NIH, 2022). They also feature presynaptic autoreceptors that regulate neurotransmitter release via feedback loops. Dysfunction within these terminals is a hallmark of several neurological and psychiatric conditions, including Parkinson's disease, where dopaminergic terminals degenerate, and clinical depression, involving altered monoamine signaling (PubMed, 2021). Pharmacological intervention often focuses on modulating the activity of these transporters and enzymes to restore chemical balance in the brain.

Other names

Monoaminergic nerve endingPresynaptic boutonMonoamine terminalMonoaminergic synapse

Drugs targeting these terminals typically act by inhibiting reuptake transporters (DAT, SERT, NET), inhibiting vesicular storage (VMAT2), or inhibiting degradative enzymes (MAO) to modulate the concentration of monoamines in the synaptic cleft.